Ipilimumab and tremelimumab are two well-characterized anti-CTLA-4 antibodies, the first approved for treatment of malignant melanoma, colorectal cancer, and renal cell carcinoma and the second being tested in clinical trials on colorectal cancer and lung cancer patients (145–151). The gene discussed is CTLA4; the disease is colorectal cancer.